Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20
subjects will be treated with placebo and NBMI 300 mg in a cross-over design. In case of
subject drop-outs, additional subjects may be enrolled as decided by the Sponsor, to allow
for expected number of evaluable subjects in each group.